Глава 5. Применение антипсихотических препаратов 251

ter international trial. Presented at the 36th an­nual NCDEU meeting. Boca Raton, FL, May 1996.

35. Beasley CM, Tran P, Tamura RN, et al. Olanzapine versus haloperidol: results of the multi-center in­ternational trial. Presented at the 35th Annual Meet­ing of the ACNP, San Juan, PR, December 1996.

36. Street JS, Tamura R, Sanger T, Tollefson G. Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Presented at the 36th Annual NCDEU "Meeting. Boca Raton, FL, May 1996.

37. Schooler NR, Kane JM. Research diagnosis for tar-dive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487.

38. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 1992; 10: 25-33.

39. Costa JF, Cutler NR, Sramek JJ, et al. Rapid dose-escalating safety, tolerability and pharmacokinetic study of sertindole 4 to 24 mg in schizophrenic patients. Presented at the 156th Annual Meeting of the American Psychiatric Association. New York, NY, May 1996.

40. McEvoy J, Borison R, Small J, et al. The efficacy and tolerability of sertindole in schizophrenic patients: a pilot, double-blind, placebo-control­led, dose ranging study. Schizophr Res 1993; 9 (2, 3): 244.

41. Van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of ser­tindole in patients with schizophrenia. Psychop-harmacology 1996; 124:168-175.

42. Daniel DG, Schmitz PJ, Holgate KL, et al. Two open-label, long-term safety studies of sertindole. Presented at the 156th Annual Meeting of the American Psychiatric Association. New York, NY, May 1996.

43. Daniel D, Targum S, Zimbroff 0, et al. Efficacy, safety and dose response of three doses of sertin­dole and three doses of Haldol in schizophrenia patients. Presented at th 34th Annual Meeting of the AGNP. San Juan, PR, December 1995.

44. Zimbroff DL, Mack RJ, Zborowski JG, et al. Effi­cacy and safety of three doses of sertindole and three doses of haloperidol in schizophrenic pa­tients. Presented at the 156th Annual Meeting of the American Psychiatric Association. New York, NY, May 1996.

45. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204.636, an atypical antipsychotic: efficacy and

safety in a;multicenter, ptacelro-controlled trial in patients with schizophrenia. J Clin Psycho-pharmacology 1996; 16: 158-169.

46. Simpson GM/Lee LH, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology 1978; 56: 78-80.

47. Baldessarini RJ, Gardner DM, Garver DL. Conver­sion from clozapine uxother antipsychotic drugs [Letter]. Arch Gen Psychiatry 1995; 52:1071-1072.

48. Alphs LD, Lee HS. Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry 1991; 52: 346-348.

49. Ichikawa J, Meltzer HY. Differential effects of re­peated treatment with haloperidol and clozapine and dopamine release and metabolism in the stri-atum and the nucleus accumbens. J Pharmacol Exp Ther 1991; 256: 348-357.

50. Abuzzahab FS, GillundJM. Clozapine and risperi-done in schizophrenia. Poster presentation at the 33rd Annual Meeting of the American College of Neuropsycho-pharmacology. San Juan, PR, De­cember 1994.

51. DeLeon J, Stanilla JK, White АО, Simpson GM. Anticholinergics to treat clozapine withdrawal [Letter] J Clin Psychiatry 1994; 55:119-120.

52. Daniel DG, Goldberg ТЕ, Weinberger DR, etal. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996; 153:417-419.

53- Meltzer HY, Lee MA, Ranjan R, et al. Relapse fol­lowing clozapine withdrawal: effect of neurolep­tic drugs and cyproheptadine. Psychopharmaco­logy 1996; 124: 176-187.

54. Shore D, Matthew S, Cotte J, Lieberman JA. Cli­nical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995; 21: 333-338.

55. Krasucki CG, Mackeith JAC. Severe hypertension associated with risperidone withdrawal [Letter]. Psychiatric Bull 1995; 19:452-453.

56. Joshi UP, Joshi PM. Risperidone in geriatric pa­tients with chronic psychoses and concurrent medical illnesses. New research #387. Presented at the 149th Annual Meeting of the American Psychiatric Association. New York, NY, May 1996.

57. Meterissian GB. Risperidone-induced neuroleptic malignant syndrome: a case report and review. Can J Psychiatry 1996; 41: 52-54.

58. Tarsy D. Risperidone and neuroleptic malignant syndrome. JAMA 1996; 275:446.